Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S77-S89, August 2002

The Effect of Latanoprost Compared with Timolol in African-American, Asian, Caucasian, and Mexican Open-Angle Glaucoma or Ocular Hypertensive Patients

  • Katarina Hedman, MSc

      Affiliations

    • Corresponding Author InformationReprint address: Katarina Hedman, Pharmacia Diagnostics, S-751 82 Uppsala, Sweden
    • Department of Neuroscience—Ophthalmology, Uppsala University Hospital, Uppsala, Sweden
    • Pharmacia Diagnostics, Uppsala, Sweden
    • ,
  • Lill-Inger Larsson, MD, PhD

      Affiliations

    • Pharmacia Corporation, Stockholm, Sweden

Abstract 

Objective: To study the intraocular pressure (IOP) reduction of latanoprost or timolol in a heterogeneous global population. Methods: A total of 1,389 glaucoma or ocular hypertensive patients treated with 0.005% latanoprost once daily (n = 737) or 0.5% timolol twice daily (n = 652) from eight clinical trials were included. After 3–6 months of treatment, the IOP was analyzed with use of analysis of covariance. Results: Latanoprost or timolol gave statistically significant mean diurnal IOP reduction in the African-American, Asian, Caucasian, and Mexican patients, latanoprost with 7.9 mm Hg and timolol with 6.4 mm Hg. The Asian and Mexican patients showed a larger difference in mean diurnal IOP reduction with use of the two drugs (range 1.8–3.1 mm Hg) than the European and U.S. patients (range 0.6–1.7 mm Hg, p = 0.030). Latanoprost produced similar mean diurnal IOP reduction in patients with and without previous glaucoma treatment other than prostaglandins. Conclusion: Latanoprost or timolol statistically significantly reduced the mean diurnal IOP in a heterogenous global population in eight clinical trials. The degree of reduction appeared to be clinically useful. The greatest difference in the mean diurnal IOP-lowering effect of latanoprost or timolol was observed in Mexican and Asian clinical trials.

Keywords:  intraocular pressure, latanoprost, ocular hypertension, open-angle glaucoma, prostaglandin, timolol

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by Pharmacia Corporation, Peapack, New Jersey, USA. Katarina Hedman is employed by Pharmacia Diagnostics, Uppsala, Sweden, and Lill-Inger Larsson is employed by Pharmacia Corporation, Stockholm, Sweden. Neither of the authors reported any proprietary interest in the development or marketing of drugs used in the clinical trials subject to this article. Presented in part at the European Society of Ophthalmology meeting in Stockholm, Sweden, June 1999 and the 6th Congress of the European Glaucoma Society, UK, London, June 2000. The authors wish to thank Adam Taube, PhD, Department of Information Science–Statistics, Uppsala University, Uppsala, Sweden; Albert Alm, MD, Department of Neuroscience–Ophthalmology, Uppsala University Hospital, Uppsala, Sweden; and Berith Ahlsten, BSc, Hospital Pharmacy, Uppsala University Hospital, Uppsala, Sweden, for valuable contributions.

PII: S0039-6257(02)00310-7

Survey of Ophthalmology
Volume 47, Supplement 1 , Pages S77-S89, August 2002

Article Tools

* Image Usage & Resolution